[{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Biosight","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Merger","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biosight \/ Ayala Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Biosight \/ Ayala Pharmaceuticals"},{"orgOrder":0,"company":"Biosight","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Merger","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biosight \/ Ayala Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Biosight \/ Ayala Pharmaceuticals"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Immunome","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Immunome"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"Immunome \/ J.P. Morgan"},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"Immunome \/ J.P. Morgan"},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immunome","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"Immunome \/ J.P. Morgan"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Merger","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Merger","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Immunome","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Immunome"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Varegacestat","moa":"||PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Immunome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunome \/ Undisclosed"},{"orgOrder":0,"company":"Immunome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunome \/ Undisclosed"},{"orgOrder":0,"company":"Immunome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunome \/ Undisclosed"},{"orgOrder":0,"company":"Immunome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Varegacestat","moa":"PSEN1\/PSENEN\/NCSTN\/APH1A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunome \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Varegacestat
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
